Puma Biotechnology
PBYI
137 hedge funds and large institutions have $2.61B invested in Puma Biotechnology in 2014 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 61 increasing their positions, 34 reducing their positions, and 13 closing their positions.
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
79% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 34
19% more funds holding
Funds holding: 115 → 137 (+22)
5% more capital invested
Capital invested by funds: $2.49B → $2.61B (+$127M)
0.41% less ownership
Funds ownership: 83.84% → 83.44% (-0.41%)
16% less call options, than puts
Call options by funds: $13.7M | Put options by funds: $16.4M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$43.8M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$38.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$20.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.2M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$67.5M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$41.5M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.8M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$6.89M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.21M |
PBYI Hedge Fund Activity: Q1 2014 in Review
137 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2014, worth a combined $2.61B — up 5.1% from $2.49B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new PBYI positions and 13 closed out — a net gain of 22 holders — while 61 added to existing stakes and 34 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $43.8M. The largest seller was Fidelity Investments, cutting an estimated $67.5M.
- 137 institutional investors held Puma Biotechnology (PBYI) as of Q1 2014, up from 115 in Q4 2013.
- Funds reported $2.61B of Puma Biotechnology stock for Q1 2014, up 5.1% quarter-over-quarter.
- 35 funds opened new Puma Biotechnology positions in Q1 2014 and 13 closed out, a net change of +22 holders.
- The largest Puma Biotechnology buyer in Q1 2014 was Citadel Advisors, an estimated $43.8M added.
- The largest Puma Biotechnology seller in Q1 2014 was Fidelity Investments, an estimated $67.5M sold.
Based on aggregated 13F filings for Q1 2014.